We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

14 hedge funds and large institutions have $4.58M invested in Chemomab Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.03% less ownership

Funds ownership: 0.36% → 0.33% (-0.03%)

57% less capital invested

Capital invested by funds: $10.6M → $4.58M (-$6.06M)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$59.3K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$23.1K
3
Morgan Stanley
Morgan Stanley
New York
+$2.35K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$661K
2
IC
Ikarian Capital
Texas
-$150K
3
BFM
Boothbay Fund Management
New York
-$49.2K
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$41.2K
5
AWM
Activest Wealth Management
Florida
-$24.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$3.56M -$661K -84,225 -13%
CAM
2
Cormorant Asset Management
Massachusetts
$458K – – –
IC
3
Ikarian Capital
Texas
$342K -$150K -19,171 -24%
KPWS
4
Kestra Private Wealth Services
Texas
$49.7K – – –
Two Sigma Investments
5
Two Sigma Investments
New York
$48.1K +$59.3K +7,566 New
BFM
6
Boothbay Fund Management
New York
$42.2K -$49.2K -6,270 -49%
Two Sigma Advisers
7
Two Sigma Advisers
New York
$18.8K +$23.1K +2,950 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$18.7K – – –
ASN
9
Advisory Services Network
Georgia
$17.8K – – –
Morgan Stanley
10
Morgan Stanley
New York
$12.4K +$2.35K +300 +18%
Osaic Holdings
11
Osaic Holdings
Arizona
$4.33K -$7.16K -913 -57%
NFSG
12
Newbridge Financial Services Group
Florida
$1.75K – – –
UBS Group
13
UBS Group
Switzerland
$653 -$8.27K -1,054 -91%
Envestnet Asset Management
14
Envestnet Asset Management
Illinois
– -$41.2K -3,215 Closed
AWM
15
Activest Wealth Management
Florida
– -$24.3K -1,900 Closed
CS
16
Credit Suisse
Switzerland
– -$3 – –

CMMB Hedge Fund Activity: Q1 2023 in Review

14 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2023, worth a combined $4.58M — down 57% from $10.6M a quarter earlier.

Fund positioning in CMMB was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 5 trimmed.

The largest buyer was Two Sigma Investments, opening a new position worth an estimated $59.3K. The largest seller was OrbiMed, cutting an estimated $661K.

  • 14 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $4.58M of Chemomab Therapeutics stock for Q1 2023, down 57% quarter-over-quarter.
  • 2 funds opened new Chemomab Therapeutics positions in Q1 2023 and 2 closed out, a net change of 0 holders.
  • The largest Chemomab Therapeutics buyer in Q1 2023 was Two Sigma Investments, an estimated $59.3K added.
  • The largest Chemomab Therapeutics seller in Q1 2023 was OrbiMed, an estimated $661K sold.

Based on aggregated 13F filings for Q1 2023.